Phase II trial of GM-CSF [granulocyte-macrophage colony-stimulating factors] in women with asymptomatic ovarian, primary peritoneal, or tubal carcinoma.

Trial Profile

Phase II trial of GM-CSF [granulocyte-macrophage colony-stimulating factors] in women with asymptomatic ovarian, primary peritoneal, or tubal carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 May 2017

At a glance

  • Drugs Granulocyte-macrophage colony-stimulating factors
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2012 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov
    • 27 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Aug 2009 Bayer added as trial sponsor, lead trial centres and planned number of patients changed from 36 to 70 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top